Mountain Valley MD Holdings Inc. (the “Company” or
“MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to
provide a broad business update of its progress across its three
core lines of business:
- Nutraceuticals - novel innovations through the Company’s
Quicksome™ technology that are designed to improve the
administration and efficacy of nutraceutical health and wellness
products;
- Agriculture – the Company’s licensed Agrarius
agricultural plant signaling technology that is designed to
organically drive increases in crop yields and overall plant
health; and
- Husbandry Animals/Aquatic Species - the application of
solubilized drugs through the Company’s Quicksol™ technology that
is designed to positively impact the health of husbandry animals
and aquatic species.
“We believe are at a very exciting time in our Company’s
progress. The MVMD team and our extensive network of partners has
made significant progress advancing our commercialization
priorities,” stated Dennis Hancock, President & CEO of Mountain
Valley MD. “We are confident that the tangible value proposition of
our technologies is being very well received and that we have
successfully laid the groundwork needed to support our long-term
commercial viability, while supporting our desire to make a global
impact in line with our vision of More Life.”
BUSINESS UPDATES
NUTRACEUTICALS
Quicksome™ Powered Eons Deeper Sleep Product Launched
MVMD’s contracted manufacturing partner in the U.S. (“Lead
Manufacturer”) has completed the set-up and testing of equipment to
enable the proprietary production of nutraceutical applications for
MVMD’s Quicksome™ technology, including sublingual rapid dissolve
tablets and powders. The GMP manufacturing and initial consumer
order fulfilment for the first product to embody the Quicksome™
technology was completed in February 2024 with the Eons Deeper
Sleep rapid dissolve mushroom tablet product. The Eons product was
produced by Circadian Wellness Corp. (“CW”) under license from MVDM
and is available to purchase directly from the CW’s website at
eons.com.
The Company has demonstrated through third-party and in-house
studies that its patented liposomal Quicksome™ technology uses
proprietary formulations and stabilizing agents to encapsulate
active ingredients, enabling a more optimized delivery into the
body through sublingual applications when compared to orally
consumed pills. When the Quicksome™ technology is consumed
sublingually, the Company believes there is an increase in the
overall efficacy of the active ingredients, a reduction in
variability of impact, and promotes the ability to use less actives
versus competitive products.
The Company’s formulators completed and transferred three
proprietary formulations for initial product creations for CW’s
Eons brand, targeting the launch of Deeper Sleep, and expanded to
energy, and immunity enhancements under a fees-for-service
agreement. The launch of CW's mushroom-infused sublingual sleep
product marked the beginning of a series of consumer products that
Eons will have the option to launch in the future under its licence
and as it determines. Although outside of MVMD’s control, it is
anticipated that a variety of consumer products that embody MVMD’s
technology under CW’s Eons brand will be available for sale in the
United States ongoing through the 2024 calendar year and
beyond.
To date, the Company has worked on a range of formulations for
Quicksome™-powered product applications, including sleep, energy,
appetite suppressant, cognition, immunity, calm, and pain relief.
Completed formulations and GMP quality product samples under the
Company’s “Mountains of™” brand now enable the Company to pursue
business development opportunities with its Lead Manufacturer, who
has a broad list of clientele who currently purchase “white label”
and proprietary products.
In 2023, the Company filed for, and was granted, trademark
protection with the United States Patent and Trademark Office for
its proprietary “MOUNTAINS OF …™” brand in the effort to secure the
option to create unlimited future product applications. The Company
believes this will be valuable in its business development efforts
and broad growth plans for its nutraceutical line of business.
AGRICULTURE
Agrarius Trial Results Exceeding Management’s
Expectations
MVMD is a licensed reseller of Agrarius, a certified organic
agricultural product, that when administered, is designed to
activate a plants’ “defense mechanisms” at the cellular level,
without the actual stress factor. The intended effect of Agrarius
is that treated plants grow deeper roots and open up their foliage
to optimize the effect of photosynthesis, thus increasing growth
hormones, plant efficiency for water use and nutrients, decreasing
the requirement of fertilizer where used, and increasing overall
resistance to diseases and stressed climate conditions.
Agrarius has been tested across numerous major agricultural
crops, and has demonstrated its ability to naturally increase crop
yields from approximately ten to fifty percent or more depending on
crop type, reduce fertilizer usage where used by more than thirty
percent, and increase general resilience to pests and climate
change forces such as drought.
MVMD believes Agrarius presents a significant opportunity to
support its growth objectives and is currently conducting business
development activity in Mexico, Central America, South America, and
the United States of America. The focus of the current business
development activities has been to target large scale farming
operations to induce trial activity on crops that would demonstrate
the benefit to improving crop yields and overall plant health.
There are currently more than 30 active crop trials being
conducted by targeted large scale farming operations, which would
represent a potential multi-million dollar field coverage pipeline
if the clients were to purchase Agrarius product from the Company
after successful trial completion and related government
registrations that enable the sale of the product. It is
management’s view that the business development effort has been
well received by the initial large scale farming operations the
Company has been targeting and working with for trialing.
Completed trials that have been documented through MVMD farming
prospects and MVMD directly managed trials over the past year have
exceeded management’s expectations. Beyond validating the
anticipated yield improvements, the Company has seen the potential
for unique pest and disease management applications as recently
demonstrated in a trial conducted by a Valencia citrus producer,
and verified by an independent laboratory that worked directly with
the farm.
In what the Company believes could be a landmark trial, Agrarius
has shown potentially promising results in mitigating Huanglongbing
(HLB), a globally destructive citrus greening disease that is
currently declared as incurable*. Treated citrus trees exhibited
notable recovery signs, including the emergence of healthy green
foliage, abundant and large white flowers, and the production of
spot-free, juicy Valencia oranges, with an anticipated overall
yield increase of approximately 10%. The Agrarius test plot
improved visual health indicators, and has also demonstrated an
enhanced distribution of both macronutrients and micronutrients
within the plant system. The Company believes these findings to be
materially significant and highlight Agrarius as a potential
organic solution for citrus producers facing the impacts of HLB,
with potentially the first viable method for revitalizing affected
orchards and introducing sustainable disease management
practices.
The Company anticipates revenue from Agrarius sales activity in
the 2024 calendar year based on the anticipated timing for
registration approvals and logic of the crop trialing cycle during
which farming organizations aim to personally validate on their
respective farms the anticipated positive impact on crop yields
and/or fertilizer reduction. The Company had anticipated sales
activity to occur by the end of the calendar year 2023, however the
Company is subject to the timelines associated with the
registration process in each jurisdiction which are in part outside
of the Company’s control. Management does not anticipate any
challenges to obtaining registrations at this time in its initial
focus markets of Brazil, Panama, Colombia, Uruguay, Costa Rica, and
Mexico.
MVMD has hired key team members in South America who are
familiar with local language, customs and trade requirements to
support its agriculture line of business in Mexico, Central America
and South America (LATAM), including in the areas of finance,
operations, business development, and agronomy.
The Company plans to operate its LATAM sales operations through
subsidiaries, including in Panama, to facilitate the registration
and distribution of the Agrarius product for sale in various
jurisdictions. The Company has also contracted the services of a
Panamanian distribution company, the location providing for certain
tax advantages, and has arranged the delivery of Agrarius product
to support sales fulfillment in LATAM once registrations are
completed in various jurisdictions over the coming months. The
initial business development strategy of the Company in LATAM
focused on Colombia, Brazil, Uruguay, Panama and Mexico, but has
been expanding to meet the demand from interested parties,
including to Costa Rica, Argentina and Bolivia.
The Company believes that it has interested customers who have
trialed the product and would be likely to proceed with product
orders once registrations allow Agrarius to be broadly applied on
their crops. Agrarius is currently registered for sale in 41 states
in the USA, with additional state approvals anticipated through the
2024 calendar year. As the LATAM registration process has been
taking longer than anticipated by the Company, the Company has
started a more concentrated effort on targeted sales activities in
the USA in states in which registrations have already been
obtained, including an immediate focus on citrus growers.
HUSBANDRY ANIMALS / AQUATIC SPECIES
Plans to Introduce Soluvec™ 1% Coated Fish Feed in Bangladesh
by May of 2024
The Company has applied its Quicksol™ solubilization technology
to the drug Ivermectin to create its Soluvec™ 1% product
formulation, which was designed to provide a safer and more
effective solution that can be administered broadly across the
husbandry animal and aquatic species marketplace.
The Company previously disclosed positive outcomes of multiple
pharmacokinetic trials that were conducted under the supervision of
The People's Republic of Bangladesh’s Ministry of Fisheries &
Livestock for an injectable Soluvec™ 1% solubilized Ivermectin
technology, and Soluvec™ 1% coated standard fish feed across farmed
fish species. The trials indicated that Soluvec™ 1% is 2,500 times
more soluble than standard Ivermectin, enhancing its efficacy and
its ability to be absorbed. In aquaculture, Soluvec™ 1% treated
feed led to enhanced growth and survivability outcomes in species
like Indian Catfish and Tilapia, indicating potentially substantial
benefits for biomass production.
The Company entered a license agreement with a privately held
Ontario corporation (the “Licensee”) for its Soluvec™ 1% animal
husbandry applications for the territory of the People's Republic
of Bangladesh. In exchange for a royalty percentage against net
sales, the agreement provides the Licensee with the exclusive
rights, within Bangladesh, to work through its partners inside the
territory to coordinate Soluvec™ 1% manufacturing and distribution
of related Soluvec™ 1% products, both in injectable and food
coating applications.
Management has been advised by the Licensee that the Licensee
has received necessary government approvals and completed the
manufacturing agreements that enable the Licensee to commence
manufacturing of the Soluvec™ 1% coated standard fish feed for
farmed fish species within Bangladesh. The Licensee has confirmed
it is working with its manufacturing partner to commence production
and finalizing plans to introduce Soluvec™ 1% coated standard fish
feed in Bangladesh by May of 2024.
The Company continues to evaluate the opportunity to license its
Soluvec™ 1% product in territories outside of Bangladesh.
Management’s belief is that the government product approval from
Bangladesh granted to the Licensee for farmed fisheries enables the
Company to look at strategic business development initiatives
outside of Bangladesh in line with anticipated product production
in Bangladesh in the 2024 calendar year. The Company believes that
sending commercially manufactured samples of the Soluvec™ 1%
product will reduce costs and enable several independent evaluation
trials to happen simultaneously with potential key partners in a
variety of territories.
To safeguard its intellectual property and the Company’s
licensing royalty model, the Company has initially filed for
Quicksol™ patent protection in key markets it has deemed
strategically important at this time for expansion outside of
Bangladesh. MVMD has filed for Soluvec™ protection in 12 additional
markets outside of the United States, including Canada, China,
India, Mexico, Sri Lanka, Thailand, Philippines, Malaysia, Brazil,
Peru, Argentina, and Chile.
APPOINTMENT OF CFO
The Company is pleased to announce the appointment of Matt
Anderson, CPA, CA, to the role of Chief Financial Officer,
replacing Yong Yao effective immediately. Mr. Anderson is a
seasoned executive, who brings 20 years of financial experience to
MVMD’s team. Mr. Anderson brings a wealth of expertise in public
company financial reporting, mergers and acquisitions, and complex
financial instruments. His background includes public market
engagements for CSE and TSXV listed companies, working with Latin
American subsidiaries and managing audit engagements with firms
such as PricewaterhouseCoopers LLC, MVMD’s current auditor.
Mr. Anderson holds a Bachelor of Commerce from McGill University
in Montreal, and has served as the Managing Director of Malaspina
Consultants since 2018, where he leads a team of skilled
accountants along with his business partners, who provide
accounting services to a broad clientele. Since July 2009, his
tenure at Malaspina Consultants Inc. has been marked by CFO and
accounting roles for various public and private companies across
multiple industries. Previously, Mr. Anderson worked with a large
auditing firm.
“I am very pleased to welcome Matt Anderson to the MVMD team to
support this important growth phase of our Company,” said Dennis
Hancock, President & CEO of MVMD. “Mr. Anderson brings
extensive public markets experience and has a deep network of
financial experts that will be valuable as we scale up our
business.”
References
* - United States Department of Agriculture, Animal and Plant
Health Inspection Service. (n.d.). Citrus Greening. Retrieved
February 16, 2024, from
https://www.aphis.usda.gov/aphis/ourfocus/planthealth/plant-pest-and-disease-programs/pests-and-diseases/citrus/citrus-greening
The Company is not making any express or implied claims that its
product(s) or intended product(s) has or have the ability to
eliminate, cure or contain any virus, ailment, disease or other
condition of plants or animals.
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.
Mountain Valley MD is building a world-class organization
centered around the implementation, licensing and reselling of key
technologies and formulations:
- patented Quicksome™ oral formulation and delivery
technologies,
- patented Quicksol™ solubility formulation technology
- licensed product reseller of Agrarius™, a novel agricultural
plant signalling technology
Consistent with its vision towards “More Life”, MVMD applies its
owned and licensed technologies to its work for advanced delivery
of molecules for human and husbandry animal applications, including
the development of products for pain management, weight loss,
energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work
with Agrarius is focused on generating a positive impact on crop
yields and reducing fertilizer usage.
MVMD’s patented Quicksome™ technology utilizes proprietary
formulations and stabilizing molecules to encapsulate and formulate
active ingredients into highly efficient product formats. The
result is a new generation of product formulations that could be
capable of delivering nutraceutical and drug molecules into the
body faster, with greater impact, efficiency and accuracy.
MVMD’s patented Quicksol™ technology covers all highly
solubilized macrocyclic lactones that could be effectively applied
in multiple viral applications that could positively impact human
and animal health globally.
MVMD’s licensed Agrarius™ agricultural plant signalling
technology is designed to be applied to crops to naturally increase
yields, reduce fertilizer usage, and increase general resilience to
pests and climate change.
For more Company information and contact details, visit
www.MVMD.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION
Certain statements contained in this news release may constitute
forward-looking information. Forward-looking information is often,
but not always, identified by the use of words such as
"anticipate", "plan", "estimate", "expect", "may", "will",
"intend", "should", and similar expressions. Forward-looking
information involves known and unknown risks, uncertainties and
other factors that may cause actual results or events to differ
materially from those anticipated in such forward-looking
information.
The Company's actual results could differ materially from those
anticipated in this forward-looking information as a result of
regulatory decisions, competitive factors in the industries in
which the Company operates, prevailing economic conditions, and
other factors, many of which are beyond the control of the
Company.
The Company is making forward-looking statements, including but
not limited to: the Company’s three (3) lines of business to
achieve commercialization; the strategy of engaging one Lead
Manufacturer and the impact thereof; the anticipated increase in
business development efforts to secure additional nutraceutical
licensing partnerships; timing for the full production readiness
for MVMD's proprietary brand products; the timing of commercial
manufacturing for Circadian, including the mushroom-infused
products under the Eons brand; the potential multi-million dollar
field coverage pipeline from trialing Agrarius customers and the
expectation trialing customers will place orders; the timing of
anticipated revenues and related ramp-up of sales growth; plans and
structure related to LATAM operations, and the impacts thereof,
including tax benefits; the registration process, the territories,
and the timing thereof; the timing of commercialization of Soluvec™
1% inside Bangladesh and the factors related thereto; and future
opportunities for Soluvec™ 1% outside of Bangladesh.
The Company believes that the expectations reflected in the
forward-looking information are reasonable, but no assurance can be
given that these expectations will prove to be correct and such
forward-looking information should not be unduly relied upon. Any
forward-looking information contained in this news release
represents the Company's expectations as of the date hereof and is
subject to change after such date. The Company disclaims any
intention or obligation to update or revise any forward-looking
information whether as a result of new information, future events
or otherwise, except as required by applicable securities
legislation.
Neither the CSE nor OTC has reviewed or approved the contents of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240301856835/en/
For further information: Dennis Hancock President and Chief
Executive Officer Mountain Valley MD Holdings Inc. Investor
Relations @ 647-725-9755 Email: info@mvmd.com www.MVMD.com
Grafico Azioni Mountain Valley MD (TG:20MP)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Mountain Valley MD (TG:20MP)
Storico
Da Dic 2023 a Dic 2024